Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 15, 2008. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility under the SmithKline Beecham Mid-Term Incentive Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on specific share transactions rather than general financial performance.
Material Changes
On October 14, 2008, the Administrators of the SmithKline Beecham Mid-Term Incentive Plan notified the Company of an increase in interests in Ordinary share ADRs for the following individuals:
- Mr. E J Gray: 17.39 ADRs
- Mr. D J Phelan: 527.30 ADRs
These transactions occurred at a price of $35.41 per ADR following the reinvestment of the dividend paid to shareholders on October 9, 2008.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The report is a compliance notification pursuant to Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Transaction Date: October 14, 2008
- Transaction Type: Increase in ADR interest via dividend reinvestment
- Price per ADR: $35.41
- Dividend Payment Date: October 9, 2008
- Signatory: Victoria Whyte, Authorised Signatory for GlaxoSmithKline plc